Simotinib

Drug Profile

Simotinib

Alternative Names: AL-6802; SIM-6802; Simotinib hydrochloride; Ximotini

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Advenchen Laboratories
  • Developer Advenchen Laboratories; Simcere Pharmaceutical Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 02 Jun 2017 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Non-small cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 15 Apr 2016 Chemical structure information added
  • 12 Apr 2016 Phase I development is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top